IMR Press / FBL / Special Issues / 1422722646663417857

The Overcoming of Multidrug Resistance in Cancer: Mechanisms and Strategies

Submission deadline: 01 March 2022
Special Issue Editors
Jing-Quan Wang, MD
Department of Pharmaceutical Sciences, St. John’s University
Interests: Cancer drug resistance; Cancer pharmacology; ABC transporters; AI-aided drug discovery
Zhe-Sheng (Jason) Chen, MD, PhD
College of Pharmacy and Health Sciences, St. John's University, 8000 Utopia Parkway, Queens, New York, NY, USA
Interests: Cancer pharmacology; Drug discovery; Multidrug resistance (MDR)
Special Issue and Collections in IMR journals
Qingbin Cui, MD
Department of Cancer Biology, College of Medicine and Life Sciences, University of Toledo, Toledo, United States
Interests: Medicinal Chemistry; Cancer Pharmacology; Drug Resistance
Special Issue Information

Dear Colleagues,

Cancer has been one of the major causes of death worldwide. Administration of conventional anticancer drugs is the first choice in clinical practice for cancer patients. Though an increasing number of target-specific small-molecule drugs were developed in the past decades, many patients relapse as treatment proceeds. Cancer drug resistance to structurally distinct chemotherapeutic agents is one of the major causes of the failure of the curative treatment. Therefore, overcoming drug resistance in cancer remains a major obstacle to successful cancer therapy.

Mechanisms of drug resistance include, but are not limited to, gene mutation or increased anti-apoptosis, DNA repairs, detoxification systems, drug inactivation or drug transport that works either independently or collaboratively. For example, the overexpression of drug transporters allows cancer cells to actively extrude chemotherapeutic agents and worsen the prognosis of cancer patients.

Extensive efforts have been made to overcome cancer multidrug resistance (MDR), including discovering new drug resistance mechanisms, therapeutic targets and new therapeutic approaches. However, overcoming drug resistance is still a challenging task, thus, a deeper understanding will benefit the development of these new strategies. This special issue accepts submissions relevant to studies on drug resistance mechanisms as well as the development of novel therapeutic agents, in order to collect state-of-the-art discoveries to circumvent cancer MDR.

Dr. Jing-Quan Wang, Prof. Dr. Zhe-Sheng Chen and Dr. Qingbin Cui

Guest Editors

Drug resistance
Manuscript Submission Information

Manuscripts should be submitted via our online editorial system at by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 2500 USD. Submitted manuscripts should be well formatted in good English.

Published Paper (1 Paper)
Open Access Original Research
ABCB1 limits the cytotoxic activity of TAK-243, an inhibitor of the ubiquitin-activating enzyme UBA1
Zhuoxun Wu, Yuqi Yang, Zining Lei, Silpa Narayanan, ... Zhesheng Chen
Front. Biosci. (Landmark Ed) 2022, 27(1), 5;
Back to top